Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akari Therapeutics plc (AKTX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including current reports, registration statements, and proxy materials related to its oncology ADC platform. These documents are a primary source for understanding how Akari describes its PH1 spliceosome-modulating payload, lead ADC candidate AKTX-101, and broader corporate strategy.
Through Forms 8-K, Akari reports material events such as equity financings, warrant issuances, note offerings and exchanges, manufacturing partnerships, and leadership changes. Recent 8-K filings detail registered direct offerings and concurrent private placements, the terms of Series E, Series F, and Series G warrants, exchanges of unsecured promissory notes into equity-linked securities, and the company’s plans to use net proceeds for research and development, working capital, and general corporate purposes. Other 8-Ks describe Nasdaq minimum bid price deficiency notices and the company’s responses.
Akari’s registration statements, including shelf registrations and resale S-1 filings, outline the structure of its American Depositary Shares, the number of ordinary shares underlying various warrant series, and risk factor discussions related to its status as a development-stage oncology company without approved products or product revenue. These filings also summarize the company’s focus on developing ADCs with novel payloads and the role of its ADC discovery platform.
Proxy statements (DEF 14A) provide detail on shareholder meetings, resolutions related to share sub-division, warrant exercisability, authority to allot shares, and adoption of new articles of association. They also describe voting procedures for ordinary shareholders and ADS holders.
On Stock Titan, Akari’s SEC filings are updated in near real time from EDGAR and paired with AI-powered summaries that highlight key terms, capital structure changes, and regulatory milestones. Users can quickly scan 10-K or 20-F style risk discussions (when available), 10-Q or 6-K interim updates, and Form 4 insider transaction reports, then drill into the full text for deeper analysis of how financing, governance, and listing matters intersect with the company’s PH1-based ADC development plans.
Deutsche Bank Trust Company Americas filed Post-Effective Amendment No. 4 to Form F-6 for Akari Therapeutics, Plc (f/k/a Celsus Therapeutics) to change the American Depositary Share ratio so that one ADS represents eighty thousand (80,000) ordinary shares. The amendment is dated March 18, 2026 and the filing was signed on March 31, 2026. The amendment revises the form of ADR/Receipt and updates the Deposit Agreement; existing receipts need not be exchanged but will be governed by the amended terms when surrendered or reissued.
Akari Therapeutics, Plc is an oncology company focused on next‑generation antibody‑drug conjugates built around its proprietary PH1 payload, which targets RNA splicing to kill cancer cells and generate immune‑stimulating neoantigens. The lead ADC, AKTX‑101, targets Trop‑2 and has shown stronger preclinical tumor killing and favorable tolerability versus existing Trop‑2 ADCs, including synergy with checkpoint inhibitors.
Akari is preparing AKTX‑101 for IND‑enabling work and aims to start a first‑in‑human Phase 1 trial by late 2026 or early 2027, while advancing CEACAM5‑directed AKTX‑102. The company highlights a history of operating losses, material weaknesses in internal controls, significant capital needs, and extensive regulatory and competitive risks. It relies on WuXi Biologics/XDC for GMP manufacturing and holds a global patent estate around PH1, AKTX‑101 and broader spliceosome‑modulating ADC biology.
Akari Therapeutics, Plc is changing the ratio of its American Depositary Shares to ordinary shares from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares. This ratio change produces a one-for-forty reverse split of the issued and outstanding ADSs only.
The ratio change is expected to be effective on or about March 31, 2026 and is intended to help the company maintain compliance with Nasdaq’s minimum bid price requirement. The company’s underlying ordinary shares are unchanged, and the ADSs will continue to trade on the Nasdaq Capital Market under the symbol AKTX.
No fractional new ADSs will be issued. Instead, fractional entitlements will be aggregated and sold, and net cash proceeds after fees, taxes and expenses will be distributed to affected ADS holders by the depositary bank, Deutsche Bank.
Akari Therapeutics director Neal James increased his economic exposure to the company on December 16, 2025 by acquiring derivative securities tied to its American Depositary Shares (ADSs).
He obtained a total of 11,132 warrants and pre-funded warrants to purchase ADSs through a private placement and a note cancellation and exchange agreement. The PIPE pre-funded warrants and accompanying Series G Warrants, as well as additional note-exchange warrants, are exercisable only upon shareholder approval. The pre-funded warrants carry a stated conversion exercise price of $0.00001 per ADS.
Akari Therapeutics investor Ray Prudo has updated his ownership in a Schedule 13D/A Amendment No. 10. He is reported to beneficially own 8,391,326,467 ordinary shares, representing 8.9% of Akari’s ordinary shares, based on 91,567,009,533 shares outstanding as of March 1, 2026.
The filing reflects December 17, 2025 transactions where Dr. Prudo purchased Series G Warrants and Pre-Funded Warrants in a private placement and additional Note Exchange Warrants and Pre-Funded Warrants in a note cancellation and exchange, all at a combined price of $0.4041 per warrant pair, using personal funds.
Samir R. Patel reports beneficial ownership of 9,725,215,000 ordinary shares of Akari Therapeutics Plc, representing 10.4% of the company’s ordinary shares outstanding as of March 1, 2026. The shares are tied to Akari’s ordinary shares, which trade in ADS form on Nasdaq under the symbol AKTX.
The stake consists of 285,336,000 ordinary shares held directly by Dr. Patel, 6,062,010,000 shares held through PranaBio Investments LLC, 1,579,785,000 options exercisable within 60 days, and 1,798,084,000 shares underlying prefunded warrants exercisable within 60 days. Dr. Patel manages PranaBio and may be deemed the beneficial owner of its holdings.
The update reflects a December 17, 2025 private placement in which Dr. Patel bought Series G warrants, Note Exchange warrants, and prefunded warrants to purchase ADSs, all funded from his personal funds. Additional warrants for up to 5,450,454,000 shares are excluded because of a 9.99% beneficial ownership limitation.
Akari Therapeutics Plc amendment reports that Hoyoung Huh, M.D., Ph.D. beneficially owned 18,199,697,667 ordinary shares, representing 18.4% of the class based on March 1, 2026 share count. The filing states each ADS represents 2,000 Ordinary Shares and discloses excluded warrants that are "subject to a 9.99% beneficial ownership limitation."
Akari Therapeutics, Plc reported results of a special general meeting where shareholders approved several warrant-related resolutions tied to prior financings and note exchanges. The meeting was held on March 2, 2026, with 91,567,009,533 ordinary shares entitled to vote, and all proposals passed.
Shareholders approved, for Nasdaq Listing Rule 5635(c) and 5635(d) purposes, the exercisability and related issuances for Series G Warrants and Placement Agent Warrants covering up to 10,043,774 and 504,300 American Depositary Shares, respectively. They also approved the exercisability of various Pre-Funded, Series G, and Note Exchange Warrants covering multiple blocks of ADSs issued in December 2025 transactions.
Akari Therapeutics, Plc is asking shareholders to approve the exercisability of several warrant issuances tied to recent financings and a note exchange. Five ordinary resolutions cover Series G Warrants, Pre-Funded Warrants, Note Exchange Warrants and Placement Agent Warrants issued in a registered direct offering, a concurrent private placement and a note exchange completed in December 2025 and January 2026.
The proposals would permit exercise of warrants for up to 10,043,774 ADSs plus 504,300 ADSs from placement agent warrants in the registered direct deal, 5,127,426 ADSs from the private placement, and 19,005,406 ADSs from the note exchange. If all Pre-Funded, Series G, Note Exchange and Placement Agent Warrants are exercised for cash, Akari states it could receive approximately $8.9 million in gross proceeds.
The board unanimously recommends voting in favor of each warrant exercise proposal and explains that without approval, the warrants cannot be exercised and the company would need to call additional shareholder meetings, adding cost. The proxy also explains detailed voting procedures for ordinary shareholders and ADS holders and outlines current major shareholdings.